Trial Profile
Mood Stabilizer Plus Antidepressant Versus Mood Stabilizer Plus Placebo in the Maintenance Treatment of Bipolar Disorder
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 18 Aug 2023
Price :
$35
*
At a glance
- Drugs Bupropion (Primary) ; Escitalopram (Primary)
- Indications Bipolar I disorders
- Focus Therapeutic Use
- 03 Aug 2023 Primary endpoint (Patients who respond to acute treatment with an antidepressant in combination with a mood stabilizer) has not been met, according to results published in the New England Journal of Medicine.
- 03 Aug 2023 According to results published in the New England Journal of Medicine Status changed to discontinued.
- 03 Aug 2023 Results assessing efficacy of adjunctive escitalopram or bupropion XL as compared with discontinuation of antidepressant therapy in patients with bipolar I disorder published in the New England Journal of Medicine